Lupus & antiphospholipid syndrome
Lupus Nexus: developing a prospective registry, biorepository and data exchange platform to foster global collaborations, accelerate research innovation and advance precision medicine in lupus
Study context
- Population
- Adults living with lupus; Lupus Landmark Study (LLS) planned enrolment up to 3500 into four cohorts, followed over 5 yearsenrolled as of 25 March 2026
- Participants
- 705 adults
- Exposure
- New onset vs Extrarenal flare vs Active LN vs Prevalent
- Outcome
- Enrolment by cohort
- Follow-up
- As of 25 March 2026
Methodological detailsstudy protocol/description, Developed with guidance from over 100 partners, Registry: medical information, clinician- and patient-reported outcomes; biorepository: whole blood, urine, saliva, stool and tissue, Data and samples available via DREAM platform, with a patient portal
- Study protocol/description
- Developed with guidance from over 100 partners
- Registry: medical information, clinician- and patient-reported outcomes; biorepository: whole blood, urine, saliva, stool and tissue
- Data and samples available via DREAM platform, with a patient portal
Main finding
As reported in the abstract
- Black participants
- 37.6%
- White participants
- 38%
- Asian/Pacific Islander participants
- 12.6%
- Unique samples collected
- Over 15 400
Observational data: associations, not effects.
Original publication
Lupus Nexus: developing a prospective registry, biorepository and data exchange platform to foster global collaborations, accelerate research innovation and advance precision medicine in lupus. Lupus Sci Med. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →